MUCOSAL VACCINE BASED IN A FRAGMENT OF RECOMBINANT TRANS-SILIDASE PROTECTS AGAINST EXPERIMENTAL ORAL CHAGAS DISEASE

PACINI, MARÍA FLORENCIA; DINATALE, BRENDA; BULFONI BALBI, CAMILA; GONZÁLEZ, FLORENCIA BELÉN; FARRÉ CECILIA; VILLAR, SILVINA RAQUEL; CHAPO, GUSTAVO; BOTTASSO OSCAR; PROCHETTO, ESTEFANÍA; MARCIPAR, IVÁN; PÉREZ ANA ROSA

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2021; 2021

SOCIEDAD ARGENTINA DE INMUNOLOGÍA

Oral Chagas disease is a frequent form of infection in some coun-tries of Latin America. Although there are drugs for its treatment,currently there are no prophylactic vaccines to combat the disease.Here, we evaluated the immunogenicity and prophylactic efficacyagainst oral infection generated by a N-terminal recombinant frag-ment of Trans-sialidase (TSNt), containing different B and T epitopesconfirmed by bioinformatics. For mucosal immunization, 10μg ofTSNt was combined with different adjuvants: c-di-AMP(A) or ISPA(I).Thus, female BALB/c mice (n=6/group) were immunized intranasally(3 doses, one every 2 weeks). As control groups we used mice notimmunized (NI) or only treated with TSNt. To evaluate the immuno-genicity, 15 days after the last immunization, we performed an invivo cell-mediated test (delayed hypersensitivity test, DHT), splenicmultifunctional T cell (IFNγ+/RORγt+) detection by flow cytometryafter in vitro stimulation with TSNt, and specific humoral responseby ELISA. Next, we evaluated prophylactic efficacy during acutephase. Thus, animals were orally challenged with 3000 Tulahuenstrain/mice (sub-lethal challenge). Parasitemia, clinical affectation(score), muscle and liver damage (plasma CK, GOT, GPT) was alsoassessed. In terms of immunogenicity, TSNt+A and TSNt+I vaccinesdeveloped an enhanced DHT until 72 h, compared to control groups(in all cases, p